Modern approach to drug therapy of tuberculosis

Tuberculosis continues to be one of the most common infectious diseases in the world, and ranks first among the causes of death from infectious diseases. About 11 million new cases of tuberculosis are registered in the world every year, and about 1.3 million patients die per year as a result of the progression of this disease. The majority of the morbidity cases occur in the underdeveloped countries of Asia and Africa, however, it is too early to speak of a complete victory over this pathology in both the European region and America. The real scourge of modern society is the development of multi-resistant forms of tuberculosis, resistant to the effects of chemotherapeutic agents, belonging to various groups. Every year, there is an increase in patients with multidrug-resistant (MDR) mycobacteria; drug resistance is especially pronounced in patients who have previously received treatment with anti-tuberculosis drugs. In this regard, one of the main principles of tuberculosis treatment at the present stage is the simultaneous prescription of two or more drugs, which is aimed at reducing the likelihood of drug resistance to them and increasing cure rates [3].